Who Should Get The First COVID Vaccines

Plus: Sizing Up A Tech Megadeal You are receiving this limited-time email resource as a subscriber to Kiplinger's free e-newsletters. To unsubscribe at any time, simply click the link in the footer below. DECEMBER 2, 2020 [View in browser]( HOW TO PROTECT AND GROW YOUR BUSINESS AND INVESTMENTS NOW Health care providers and residents and staff of long-term care facilities, such as nursing homes, should be put at the top of the priority list to receive the new COVID-19 vaccines, according to a committee that advises the Centers for Disease Prevention and Control. The recommendation must still be accepted by CDC Director Robert Redfield, but this is expected to be a formality. While state governments are not bound by the recommendation, the committee and the CDC carry a lot of influence, and it is likely that many states will adopt their recommendation. --------------------------------------------------------------- SPONSORED CONTENT FROM SMARTASSET [7 Secrets Comfortable Retirees Know About Financial Advisors]( Choosing the right financial advisor can determine your financial trajectory for years to come. [READ MORE]( --------------------------------------------------------------- State governments are being asked to submit their orders for the vaccines to Operation Warp Speed, the federal vaccine initiative, by this Friday. Shipments will start to take place after the FDA grants Pfizer’s ([PFE]( and Moderna’s ([MRNA]( vaccines an Emergency Use Authorization. A Food and Drug Administration advisory committee will vote on Pfizer’s application on December 10, and Moderna’s on December 17. Formal approval will likely take place within days of these meetings. M&A intrigue from the newest Dow component: Shares of cloud-based customer relationship management giant Salesforce.com ([CRM]( which [joined the Dow at the end of August]( sank in early trading this morning after Tuesday’s official announcement that it will buy workplace communications firm Slack Technologies ([WORK]( in a cash-and-stock megadeal worth $27.7 billion. Given the lofty stock’s importance to the price-weighted Dow, investors might want to hear what the pros have to say about this potentially transformative deal. UBS said it was “disappointed” in the too-rich price tag for Slack, as well as some recent performance metrics, but nonetheless maintained its Buy rating. Canaccord Genuity (Hold) says that while “investors are sure to gripe” about the M&A price, “Slack fills a portfolio gap for the firm … essentially creating an operating system for growth that is more relevant than ever.” And Wedbush (Outperform) calls it “a near-term pain for long-term gain poker move.” Largely, analysts have a number of good things to say, but investors, who ultimately set the price of stocks, seem to be much more bearish on the deal, at least for now. Free download, [The Kiplinger Letter's Forecast](. No information required from you. SPONSORED CONTENT FROM SMARTASSET [Find the Right Financial Advisor for You]( Ready to kick your retirement plan into high gear? Compare fiduciary financial advisors in your area. [READ MORE]( LATEST INVESTING NEWS FROM KIPLINGER.COM [Where to Invest in 2021]( [Joe Biden’s Student Loan Plan: What’s in It for You?]( [2020 Tech Gift Guide: The 10 Best Values + The 10 Best, Period]( [19 Best Costco Kirkland Signature Products to Buy for the Holidays]( [Sign Up for Kiplinger's Free Tax Tips e-Newsletter for Money-Saving Tax Planning and Tax Filing Guidance]( [Kiplinger] [Facebook]( [Twitter]( [LinkedIn]( Send this to a friend. [Click here.]( All content ©2020 The Kiplinger Washington Editors 1100 13th Street, NW, Suite 1000 Washington, D.C. 20005 Thank you for subscribing to Kiplinger's A Step Ahead, a free resource to help readers navigate the economic recovery from COVID-19. If you ever wish to stop receiving this service, please [click here to unsubscribe](.